MTHFR — gene · CancerIndex

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MTHFR A222V3
(predisposing)	Prostate Adenocarcinoma	Predisposing	B	Supports Protectiveness	4	accepted	EID1756 Study of 1817 prostate adenocarcinoma cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of prostate cancer risk in a population of Han Chinese in Shang… (full text at CIViC) PMID 27819322 · Wu et al., 2016 · Open in CIViC	civic
Fluorouracil	Rectal CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID1757 Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and 3.25 times more likely not to experience relapse (95%… (full text at CIViC) PMID 26693073 · Nikas et al., 2015 ·

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

Data not yet available

No cohort frequency recorded for this gene.

Literature

25 per page, newest first.

pubmedPublishedShowing 1–3 of 3 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.